Metabolic-associated fatty liver disease and sarcopenia: A double whammy

Table 2 Metabolic-associated fatty liver disease as a risk factor for sarcopenia[28]

Ref.	Study design	Study population	Size	Sarcopenic assessment	MAFLD assessment	Conclusions
Roh et al[25], 2022	Longitudinal	Korean	1595	DXA	Non-invasive models	The presence of NAFLD may predict future risk of low muscle mass and low muscle strength, with a greater impact on LMS than on LMM
Sinn et al[26], 2022	Cross-sectional	Korean	52815	BIA	US	Participants with NAFLD were at increased risk of sarcopenia, indicated by faster loss of skeletal muscle mass
Altajar et al[27], 2023	Cross-sectional	Korean	6414	BIA	CAP	The presence of MAFLD is significantly associated with an increased risk of low muscle mass with varying risks according to the MAFLD subgroups

BIA: Bioimpedance analysis; DXA: Dual Xray absorptiometry; LUTE: Liver ultrasound transient elastography; MAFLD: Metabolic-associated fatty liver disease; NAFLD: Non-alcoholic fatty liver disease; US: Ultrasonography; CAP: Controlled attenuation parameter; LMM: Low muscle mass; LMS: Low muscle strength.